These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 20631178)

  • 1. Role of the copper transporter, CTR1, in platinum-induced ototoxicity.
    More SS; Akil O; Ianculescu AG; Geier EG; Lustig LR; Giacomini KM
    J Neurosci; 2010 Jul; 30(28):9500-9. PubMed ID: 20631178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin ototoxicity in rat cochlear organotypic cultures.
    Ding D; He J; Allman BL; Yu D; Jiang H; Seigel GM; Salvi RJ
    Hear Res; 2011 Dec; 282(1-2):196-203. PubMed ID: 21854840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
    Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
    Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat.
    Mukherjea D; Jajoo S; Kaur T; Sheehan KE; Ramkumar V; Rybak LP
    Antioxid Redox Signal; 2010 Sep; 13(5):589-98. PubMed ID: 20214492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity.
    Pabla N; Murphy RF; Liu K; Dong Z
    Am J Physiol Renal Physiol; 2009 Mar; 296(3):F505-11. PubMed ID: 19144690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.
    Ciarimboli G; Deuster D; Knief A; Sperling M; Holtkamp M; Edemir B; Pavenstädt H; Lanvers-Kaminsky C; am Zehnhoff-Dinnesen A; Schinkel AH; Koepsell H; Jürgens H; Schlatter E
    Am J Pathol; 2010 Mar; 176(3):1169-80. PubMed ID: 20110413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating protective and therapeutic effects of alpha-lipoic acid on cisplatin-induced ototoxicity.
    Kim KH; Lee B; Kim YR; Kim MA; Ryu N; Jung DJ; Kim UK; Baek JI; Lee KY
    Cell Death Dis; 2018 Aug; 9(8):827. PubMed ID: 30068942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
    Blair BG; Larson CA; Safaei R; Howell SB
    Clin Cancer Res; 2009 Jul; 15(13):4312-21. PubMed ID: 19509135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Protein arginine methyltransferase 6 reduces reactive oxygen species production and attenuates aminoglycoside- and cisplatin-induced hair cell death.
    He Y; Li W; Zheng Z; Zhao L; Li W; Wang Y; Li H
    Theranostics; 2020; 10(1):133-150. PubMed ID: 31903111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
    Howell SB; Safaei R; Larson CA; Sailor MJ
    Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
    Jandial DD; Farshchi-Heydari S; Larson CA; Elliott GI; Wrasidlo WJ; Howell SB
    Clin Cancer Res; 2009 Jan; 15(2):553-60. PubMed ID: 19147760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.
    Blair BG; Larson CA; Adams PL; Abada PB; Safaei R; Howell SB
    Mol Pharmacol; 2010 Jun; 77(6):912-21. PubMed ID: 20194531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment.
    Landon CD; Benjamin SE; Ashcraft KA; Dewhirst MW
    Int J Hyperthermia; 2013 Sep; 29(6):528-38. PubMed ID: 23879689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective Effect of Avenanthramide-C on Auditory Hair Cells against Oxidative Stress, Inflammatory Cytokines, and DNA Damage in Cisplatin-Induced Ototoxicity.
    Umugire A; Nam YS; Nam YE; Choi YM; Choi SM; Lee S; Cho JH; Cho HH
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
    Kalayda GV; Wagner CH; Jaehde U
    J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sound preconditioning therapy inhibits ototoxic hearing loss in mice.
    Roy S; Ryals MM; Van den Bruele AB; Fitzgerald TS; Cunningham LL
    J Clin Invest; 2013 Nov; 123(11):4945-9. PubMed ID: 24216513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4.
    Tsai CY; Larson CA; Safaei R; Howell SB
    Biochem Pharmacol; 2014 Aug; 90(4):379-87. PubMed ID: 24967972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.
    Liu JJ; Jamieson SM; Subramaniam J; Ip V; Jong NN; Mercer JF; McKeage MJ
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):847-56. PubMed ID: 19466412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cells.
    Nassauer L; Schott JW; Harre J; Warnecke A; Morgan M; Galla M; Schambach A
    J Mol Med (Berl); 2024 Sep; 102(9):1163-1174. PubMed ID: 39110182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supporting Cells and Their Potential Roles in Cisplatin-Induced Ototoxicity.
    Waissbluth S; Maass JC; Sanchez HA; Martínez AD
    Front Neurosci; 2022; 16():867034. PubMed ID: 35573297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.